AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02232282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard acupuncture treatment
Description: A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
Study NCT02232282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Sham/Minimal Acupuncture
Description: Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints.
Study NCT03351790 — intervention group
Intervention type: OTHER
Intervention: Questionniare only
Description: A pre-procedure questionnaire will be completed by all participants
Study NCT00445484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly
Study NCT00445484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT03520959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LV305
Description: Administered via subcutaneous (SC) injection.
Study NCT03520959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G305
Description: Administered via intramuscular (IM) injection.
Study NCT03520959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LV305-matching placebo
Description: Administered via SC injection.
Study NCT03520959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: G305-matching placebo
Description: Administered via IM injection.
Study NCT03559036 — intervention group
Intervention type: PROCEDURE
Intervention: Locomotor Training
Description: Body-weight supported stepping on a treadmill.
Study NCT03778567 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Telbivudine
Description: CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
Study NCT02553122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evicel
Description: Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
Study NCT02553122 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: tourniquet
Description: A tourniquet is applied to the thigh to stop/ decrease blood flow
Study NCT00998270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone marrow transplantation
Description: Autologous transplantation:~* Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~* G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~* Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days
Study NCT00998270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Description: Allogeneic~* Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~* Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days
Study NCT02132884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples
Study NCT02132884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic procedure
Description: Receive standard of care treatment
Study NCT02132884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted therapy
Description: Receive specific targeted therapy
Study NCT02132884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02132884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01728415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
Study NCT01728415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
Study NCT03922542 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
Study NCT03922542 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
Study NCT02525250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Realization of 3 Blood samples during study during treatment with lenalidomide
Study NCT00626249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder
Description: Technosphere Inhalation Powder
Study NCT03959124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Brain stimulation electrodes at parameters 2.0\~4.5 V；60 μs；20 Hz
Study NCT03959124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical treatment for Alzheimer's disease
Description: Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
Study NCT03959124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment for Alzheimer's disease
Description: Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
Study NCT02489136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laying of hands (Spiritist passe)
Description: In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
Study NCT02489136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laying of hands (Spiritist passe)
Description: In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
Study NCT03648008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
Study NCT03648008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.015 mg\*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
Study NCT00560742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Coronary artery bypass grafting without bone marrow cells injection
Study NCT00560742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of bone marrow cells
Description: Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
Study NCT00560742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of bone marrow cells
Description: Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
Study NCT02101021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Tablet (s) administered orally once or twice daily
Study NCT02101021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match momelotinib
Description: Placebo to match momelotinib tablets administered orally once or twice daily
Study NCT02101021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study NCT02101021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study NCT02101021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study NCT02101021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study NCT02383095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Study NCT02383095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: metacognitive therapy
Study NCT01166100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Study NCT01166100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine Hydrochloride
Description: Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Study NCT03078712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Perfusion guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
Study NCT03078712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactate guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
Study NCT03694613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placental/Umbilical Cord Blood sample
Description: After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
Study NCT02632721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT02632721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Study NCT02663271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given at 10mg/kg IV every 2 weeks.
Study NCT02663271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
Study NCT02663271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI will be done at screening and every 8 weeks.
Study NCT02663271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
Study NCT00272064 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glulisine
Description: individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
Study NCT00272064 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glargine
Description: individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
Study NCT00272064 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1000 mg b.i.d, since the qualification phase, oral
Study NCT02527525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Study NCT01578486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salsalate
Description: open-label trial of salsalate 3g/day for 12 weeks.
Study NCT01292629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSert 251 intraocular lens
Description: aphakic intraocular lens
Study NCT04292899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion
Study NCT04292899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT02763670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PRETICARD patient care management
Description: A standardized and specialized network to take care of the severe cardiac insufficiency:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~* At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~* At 6 and 18 months, one cardiology consultation~* At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)
Study NCT02763670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: As usual  patient care management
Description: Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook).
Study NCT03950297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 609A
Description: 609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
Study NCT02657161 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RABIPUR®
Description: Biological rabies vaccine
Study NCT02657161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA rabies vaccine
Description: Biological rabies vaccine
Study NCT02657161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA rabies vaccine with an accelerated regimen
Description: Biological rabies vaccine
Study NCT03514342 — intervention group
Intervention type: PROCEDURE
Intervention: Interscalene brachial plexus block
Description: Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
Study NCT03514342 — intervention group
Intervention type: DRUG
Intervention: 0.75% ropivacaine
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
Study NCT01557933 — intervention group
Intervention type: OTHER
Intervention: No interventions will be used
Description: No interventions will be used
Study NCT03843281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: s. above
Study NCT03843281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s. above
Study NCT03843281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: s. above
Study NCT03843281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: s. above
Study NCT02031783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixture of glucose and fructose
Study NCT02031783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Study NCT00353834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
Study NCT00353834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine Insulin
Description: Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
Study NCT01927185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Axis strategy
Description: With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
Study NCT01927185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short Axis Strategy
Description: With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
Study NCT02973087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (Recombinant)
Description: OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
Study NCT02973087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant)
Description: During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
Study NCT00656773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
Study NCT00656773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
Study NCT05556278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound study
Description: based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)
Study NCT05556278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurophysiological test
Description: ultrasound protocol described by Chen et al. (2)
Study NCT01518283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 10 mg/m2
Description: Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
Study NCT02290626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elmental diet
Description: elemental diet is administered using PEG.
Study NCT02290626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semi-solid diet
Description: Semi-solid diet is administered using PEG.
Study NCT01184222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: great occipital nerve stimulation
Description: * Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.